Life science and healthcare industry executive Adam Deutsch joins uMotif board
Deutsch has a proven track record of leading major transformations in global life sciences and MedTech businesses; renowned for deep domain expertise, and for excellence in high-level operational, functional and compliance roles at public and private companies
BOSTON, Mass. – March 15, 2023 — uMotif – one of the clinical trial technology market’s fastest growing companies – bolstered its status as the leader in next-generation eCOA/ePRO with the announcement that life science and healthcare executive Adam Deutsch has joined its Board of Directors.
uMotif’s highly scalable eCOA/ePRO platform combines deep clinical knowledge and consumer design expertise to deliver unprecedented levels of patient compliance, regularly achieving greater than 90% data capture in real-world studies.
Adam Deutsch has earned a global reputation across life sciences and healthcare for his deep domain knowledge, and his depth and breadth of expertise in high-level functional and operational roles at public and private companies. He is known for his solid track record of helping companies seize transformational business opportunities while navigating regulatory complexity. In bringing strong business acumen and a thoughtful approach to transforming companies, Deutsch is focused on how to better serve the research participant.
uMotif CEO Steve Rosenberg (LinkedIn) said, “Adam has an impeccable track record of guiding the growth of private and public companies in our industry. His expertise spans technology, business and compliance, and we’re looking forward to having him help us continue expanding our reach on a global level.”
Deutsch currently serves as an Operating Advisor to Revival Healthcare Capital. Previously he was Chief Business Officer and General Counsel at global technology company Clario, which was formed by the merger of ERT and Bioclinica. While at Clario, Deutsch led several operational and functional teams, including Transformation and Integration, Corporate Development and Strategy, Legal and Compliance, Quality and Regulatory, Marketing and Communications, and Logistics and Customer Care.
Also previously, among several roles of increasing responsibility, Deutsch was Chief Transformation Officer, GM of the global Critical Care business, and General Counsel at ConvaTec Group, a FTSE 100 global MedTech company, where he also played a significant leadership role on ConvaTec’s landmark $1.8 billion IPO on the London Stock Exchange (valuing the company at over $5 billion).
Prior to that, during his tenure at Biomet, one of the world’s largest orthopedic medical device companies, Deutsch served as Corporate VP, Chief Compliance Officer, and Associate General Counsel, and was instrumental in the company’s $13.35 billion strategic merger with Zimmer Holdings, Inc.
Adam Deutsch (LinkedIn) commented, “I’ve rarely seen a company as well positioned for growth as uMotif. It’s a truly transformational company that’s at an inflection point to significantly scale. They have the team, the vision, the domain expertise, and the technology. Customers love the platform and the groundbreaking Motif interface – the first validated eCOA/ePRO data capture method in 20 years. uMotif’s leadership believes as I do that if it’s right for the patient it’s right for the business. I’m looking forward to helping the company continue to accelerate its already-strong growth.”
uMotif Chairman of the Board Steve Powell (LinkedIn) said, “We’re delighted to welcome Adam Deutsch to the uMotif Board. His expertise in creating healthcare and life science market leaders will greatly benefit uMotif as it pursues its ambitious growth plans.”
Deutsch holds a JD from New York University School of Law, and a BA in Political Science and English with High Honors from Rutgers University.
Putting patients first is in uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at www.umotif.com